- Home
- PHD vs OPTN Comparison
PHD vs OPTN Comparison
Compare PHD & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHD
- OPTN
- Stock Information
- Founded
- PHD 2004
- OPTN 2010
- Country
- PHD United States
- OPTN United States
- Employees
- PHD N/A
- OPTN N/A
- Industry
- PHD Investment Managers
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- PHD Finance
- OPTN Health Care
- Exchange
- PHD Nasdaq
- OPTN Nasdaq
- Market Cap
- PHD 121.9M
- OPTN 99.7M
- IPO Year
- PHD N/A
- OPTN 2017
- Fundamental
- Price
- PHD $9.82
- OPTN $0.48
- Analyst Decision
- PHD
- OPTN Strong Buy
- Analyst Count
- PHD 0
- OPTN 3
- Target Price
- PHD N/A
- OPTN $3.00
- AVG Volume (30 Days)
- PHD 67.7K
- OPTN 1.2M
- Earning Date
- PHD 01-01-0001
- OPTN 11-12-2024
- Dividend Yield
- PHD 11.43%
- OPTN N/A
- EPS Growth
- PHD N/A
- OPTN N/A
- EPS
- PHD 1.27
- OPTN N/A
- Revenue
- PHD N/A
- OPTN $75,672,000.00
- Revenue This Year
- PHD N/A
- OPTN $24.44
- Revenue Next Year
- PHD N/A
- OPTN $49.00
- P/E Ratio
- PHD $7.60
- OPTN N/A
- Revenue Growth
- PHD N/A
- OPTN 5.13
- 52 Week Low
- PHD $8.30
- OPTN $0.32
- 52 Week High
- PHD $9.81
- OPTN $2.10
- Technical
- Relative Strength Index (RSI)
- PHD 49.31
- OPTN 39.22
- Support Level
- PHD $9.76
- OPTN $0.32
- Resistance Level
- PHD $9.85
- OPTN $0.46
- Average True Range (ATR)
- PHD 0.06
- OPTN 0.08
- MACD
- PHD -0.00
- OPTN -0.02
- Stochastic Oscillator
- PHD 53.77
- OPTN 33.19
About PHD Pioneer Floating Rate Fund Inc.
Pioneer Floating Rate Trust is a diversified, closed-end fund. Its investment objective is to provide a high level of current income and seek the preservation of capital by investing predominantly in floating-rate loans.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.